MTOR and prostate carcinoma: Some studies in canine mammary carcinomas [25], prostatic carcinomas [26], haemangiosarcomas [27] and in canine cell lines of B-cell lymphoma, glioma and mast cell tumour cells [28] have reported that mTOR pathway and its downstream effectors are activated in dogs, suggesting the need for research directed to the potential use of these proteins not only as prognostic biomarkers but also as a target for molecular therapies aimed at these biomarkers in canine SCC, as has been studied in human cancers [24,29,30,31].